BioSpace News Archive

SeqLL Inc., announced the decision of its Board of Directors to cancel the special cash dividend and stock dividend that it intended to make to its common stockholders in connection with, and subject to, the consummation of its planned acquisition of Lyneer Investments LLC and the disposition of its current business operations.

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced the pricing of a public offering of $750 million aggregate principal amount of its 6.400% senior notes due 2033 under Quest Diagnostics’ shelf registration statement.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the first quarter ended September 30, 2023.

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the third quarter of 2023.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced topline results from EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl) in patients with Duchenne muscular dystrophy between the ages of 4 through 7 years.

Immunocore Holdings Plc announced that management will present at the following investor conferences in November:

Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients.

Ardelyx, Inc. announced between October 11, 2023 and October 29, 2023 the compensation committee of the company’s board of directors granted forty-seven new non-executive employees options to purchase an aggregate of 635,024 shares of the company’s common stock, and granted fifty-one new non-executive employees an aggregate of 591,900 Restricted Stock Units.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023, following the close of trading.